Securities code: 002873 securities abbreviation: Guiyang Xintian Pharmaceutical Co.Ltd(002873) Announcement No.: 2021-156 bond Code: 128091 bond abbreviation: Xintian convertible bond
Guiyang Xintian Pharmaceutical Co.Ltd(002873)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete without false records, misleading statements or major omissions.
1、 Description of abnormal fluctuations in stock trading
Guiyang Xintian Pharmaceutical Co.Ltd(002873) (hereinafter referred to as “the company” or “the company”) (securities code: 002873, securities abbreviation: Guiyang Xintian Pharmaceutical Co.Ltd(002873) ; bond Code: 128091, bonds abbreviation: Xintian convertible bonds) the stock trading price has deviated by more than 20% in three consecutive trading days (December 22, 2021, December 23, 2021, December 24, 2021) The relevant provisions of the trading rules of Shenzhen Stock Exchange (revised in 2021) belong to abnormal fluctuations in stock trading.
2、 Description of concerns and verification on important issues
In view of the abnormal fluctuation of the company’s stock trading, the company checked the relevant matters and asked the controlling shareholder and actual controller of the company. The relevant information is described as follows:
1. The information disclosed by the company in the early stage does not need to be corrected or supplemented;
2. The company has not found any unpublished material information that may or has had a great impact on the stock trading price of the company reported by the public media recently;
3. There is no significant change or expected to occur in the company’s recent business situation and internal and external business environment;
4. After verification, the company, the controlling shareholder and the actual controller do not have any major events that should be disclosed but not disclosed about the company, nor do they have any major events in the planning stage;
5. After verification, the controlling shareholder and actual controller did not buy or sell the company’s shares during the abnormal fluctuation of stock trading;
6. The company does not violate fair information disclosure.
3、 Description of no information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters or planning, negotiation, intention, agreement, etc. related to the matters that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Necessary risk tips
The information disclosure media designated by the company are securities daily, Shanghai Securities News and cninfo（ http://www.cn.info.com..cn. ）, all information disclosure of the company shall be subject to the announcement published in the above media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations.
The company reminds investors to fully understand and pay attention to the trading risks in the secondary market and the risk tips disclosed by the company, pay attention to investment risks and invest rationally.
It is hereby announced.
Guiyang Xintian Pharmaceutical Co.Ltd(002873) board of directors
December 24, 2021
